Evidence map›Paper›PMID 32404143›Full record

ReviewAlzheimer's research & therapy2020

Relevance of biomarkers across different neurodegenerative diseases.

Alexander J Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J Betts, Federica Capraro, Elisabeth H Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N E Young and 11 more

Erratum issued Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05451069 (Combined Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic Plasmacytoid Dendritic Cells in Defining Disease Course in Multiple Sclerosis Patients), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05451069 unknown statusnot on this mapstarted 2022, after this paper: background citation

Combined Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic Plasmacytoid Dendritic Cells in Defining Disease Course in Multiple Sclerosis Patients

TypeobservationalSponsorAssiut UniversityRan2022 to 2025Enrolled42ConditionsMultiple SclerosisArmsNeurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Sphingolipids in Emotional Well-Being.Journal of neurochemistry · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Long Non-Coding RNAs: New Insights in Neurodegenerative Diseases.International journal of molecular sciences · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. CT-based volumetric measures obtained through deep learning: Association with biomarkers of neurodegeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 7 countries.

Alexander J EhrenbergMemory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. alexander.ehrenberg@ucsf.edu.
Ayesha KhatunDementia Research Centre, University College London Institute of Neurology, London, UK.
Emma CoomansDepartment of Radiology & Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Matthew J BettsGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Federica CapraroThe Francis Crick Institute, London, UK.
Elisabeth H ThijssenMemory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Konstantin SenkevichPetersburg Nuclear Physics Institute names by B.P. Konstantinov of National Research Center, Kurchatov Institute, St. Petersburg, Russia.
Tehmina BharuchaOxford Glycobiology Institute, Department of Biochemistry , University of Oxford, Oxford, UK.
Mehrsa JafarpourDepartment of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK.
Peter N E YoungDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
William JagustHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA.
Stephen F CarterDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Tammaryn LashleyDepartment of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK.
Lea T GrinbergMemory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Joana B PereiraDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Niklas Mattsson-CarlgrenDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Jörg HanriederDepartment of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK.
Henrik ZetterbergDepartment of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK.
Michael SchöllDepartment of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK.
Ross W PatersonDementia Research Centre, University College London Institute of Neurology, London, UK.
Lund University · SENational Hospital for Neurology and Neurosurgery · GBUK Dementia Research Institute · GBUniversity of California, San Francisco · USAmsterdam Neuroscience · NLFirst Pavlov State Medical University of St. Petersburg · RUGerman Center for Neurodegenerative Diseases · DEKing's College London · GBLawrence Berkeley National Laboratory · USSahlgrenska University Hospital · SEThe Francis Crick Institute · GBUniversidade de São Paulo · BRUniversity of Cambridge · GBUniversity of Oxford · GB

Funding

PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Project 3: Autophagy dysfunction and neuronal activity in FTDU54NS100717 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI GAN, LI · 2016 to 2020
$10.8M
Neuropathological changes underlying clinical heterogeneity in Alzheimer diseaseK24AG053435 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRINBERG, LEA TENENHOLZ · 2016 to 2025
$1.8M
NIA NIH HHS K24 AG053435NIA NIH HHS P50 AG023501NINDS NIH HHS U54 NS100717
6 · The paper itself

Abstract

backgroundThe panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and increasing use, appropriate implementation and interpretation are paramount. Various biomarkers feature nuanced differences in strengths, limitations, and biases that must be considered when investigating disease etiology and clinical utility. For example, neuropathological investigations of Alzheimer's disease pathogenesis can fall in disagreement with conclusions reached by biomarker-based investigations. Considering the varied strengths, limitations, and biases of different research methodologies and approaches may help harmonize disciplines within the neurodegenerative disease field. PURPOSE OF REVIEW: Along with separate review articles covering fluid and imaging biomarkers in this issue of Alzheimer's Research and Therapy, we present the result of a discussion from the 2019 Biomarkers in Neurodegenerative Diseases course at the University College London. Here, we discuss themes of biomarker use in neurodegenerative disease research, commenting on appropriate use, interpretation, and considerations for implementation across different neurodegenerative diseases. We also draw attention to areas where biomarker use can be combined with other disciplines to understand issues of pathophysiology and etiology underlying dementia. Lastly, we highlight novel modalities that have been proposed in the landscape of neurodegenerative disease research and care.

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesAmyloid beta-PeptidesBiomarkersDisease ProgressionHumanstau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseaseAmyloidBiomarkersCerebrospinal fluidMagnetic resonance imagingNeurodegenerative diseasesNeurofilament light chainPlasma biomarkersPositron emission tomographyTau

Identifiers

PMID32404143
PMCPMC7222479
OpenAlexW3027478827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.